Bahram Valamehr compensation by year
FATE THERAPEUTICS Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $321,865 | $375,000 | $390,000 | $430,000 | $455,000 | $500,000 | $525,000 | $600,000 |
| Bonus | $0 | $0 | — | — | $0 | $0 | $147,000 | $0 |
| Stock awards | $0 | $744,750 | $549,750 | $5,375,416 | $1,327,751 | $0 | $541,000 | $0 |
| Option awards | $2,138,235 | $1,547,898 | $1,324,347 | $500,000 | $1,375,000 | $2,342,115 | $2,367,000 | $1,283,868 |
| Non-equity incentive | $117,250 | $150,938 | $195,000 | $172,000 | $0 | $140,000 | $0 | $360,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $0 | $4,500 | $4,600 | $4,700 |
| Total | $2,577,350 | $2,818,586 | $2,459,097 | $6,477,416 | $3,157,751 | $2,986,615 | $3,584,600 | $2,248,568 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: FATE THERAPEUTICS INC DEF 14A filed April 24, 2026, accession 0001193125-26-177094, and prior-year filings.
How this page was built: the FATE THERAPEUTICS INC filed document, accession 0001193125-26-177094. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 162,501 | — | $6.76 |
| Option | 12,501 | — | $6.77 |
| Option | 1,106 | — | $39.87 |
| Option | 902,779 | — | $1.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in FATE THERAPEUTICS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 24, 2026)current to 2026-11-05 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-04 | Sale | — | 43,947 | $2.46 | 591,815 |
| 2026-05-20 | Sale | — | 28,946 | $1.88 | 635,762 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
FATE THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bahram Valamehr · this page | President, Chief Executive Officer and Director | $2,248,568 |
| Cindy Tahl | Chief Legal & Compliance Officer and Corporate Secretary | $1,111,996 |
| Kamal Adawi | Chief Financial Officer and Treasurer | $714,800 |
Board service
FATE THERAPEUTICS board · FY2024–FY2025How this board is paid
Company policy: FATE THERAPEUTICS pays directors a $40,000 cash retainer. As stated in FATE THERAPEUTICS's FY2025 proxy.
The full FATE THERAPEUTICS compensation record
free company briefThis page is one person within FATE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the FATE THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order FATE THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are FATE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.